Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2015, Article ID 135023, 13 pages
http://dx.doi.org/10.1155/2015/135023
Review Article

The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy

1Cell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China
2Department of Immunology, Basic Medical College, Hebei Medical University, Shijiazhuang, Hebei 050017, China
3Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China
4Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China
5School of Nursing, Hebei Medical University, Shijiazhuang, Hebei 050000, China
6Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China

Received 23 March 2015; Accepted 6 May 2015

Academic Editor: Joost Sluijter

Copyright © 2015 Xianyun Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Go, D. Mozaffarian, V. L. Roger et al., “Heart disease and stroke statistics—2014 update: a report from the American Heart Association,” Circulation, vol. 129, no. 3, pp. e28–e292, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. R. J. Henning, “Stem cells in cardiac repair,” Future Cardiology, vol. 7, no. 1, pp. 99–117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. A. P. Beltrami, L. Barlucchi, D. Torella et al., “Adult cardiac stem cells are multipotent and support myocardial regeneration,” Cell, vol. 114, no. 6, pp. 763–776, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Hosoda, “C-kit-positive cardiac stem cells and myocardial regeneration,” American Journal of Cardiovascular Disease, vol. 2, no. 1, pp. 58–67, 2012. View at Google Scholar
  5. K. Urbanek, D. Torella, F. Sheikh et al., “Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 24, pp. 8692–8697, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Zamilpa, “Stem cell mechanisms during left ventricular remodeling post-myocardial infarction: repair and regeneration,” World Journal of Cardiology, vol. 6, no. 7, pp. 610–620, 2014. View at Publisher · View at Google Scholar
  7. D. Pangonyte, E. Stalioraityte, R. Ziuraitiene, D. Kazlauskaite, J. Palubinskiene, and I. Balnyte, “Cardiomyocyte remodeling in ischemic heart disease,” Medicina (Kaunas), vol. 44, no. 11, pp. 848–854, 2008. View at Google Scholar · View at Scopus
  8. D. Pangonyte, E. Stalioraityte, D. Kazlauskaite, R. Žiuraitiene, Z. Stanioniene, and S. Kerpauskiene, “Changes of heart geometry in patients with ischemic heart disease,” Medicina, vol. 44, no. 1, pp. 8–14, 2008. View at Google Scholar · View at Scopus
  9. R. E. Michler, “Stem cell therapy for heart failure,” Methodist DeBakey Cardiovascular Journal, vol. 9, no. 4, pp. 187–194, 2013. View at Publisher · View at Google Scholar
  10. M. Gnecchi, P. Danieli, and E. Cervio, “Mesenchymal stem cell therapy for heart disease,” Vascular Pharmacology, vol. 57, no. 1, pp. 48–55, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. M. A. Laflamme and C. E. Murry, “Heart regeneration,” Nature, vol. 473, no. 7347, pp. 326–335, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. V. F. M. Segers and R. T. Lee, “Stem-cell therapy for cardiac disease,” Nature, vol. 451, no. 7181, pp. 937–942, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Tongers, D. W. Losordo, and U. Landmesser, “Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges,” European Heart Journal, vol. 32, no. 10, pp. 1197–1206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Nadal-Ginard, J. Kajstura, A. Leri, and P. Anversa, “Myocyte death, growth, and regeneration in cardiac hypertrophy and failure,” Circulation Research, vol. 92, no. 2, pp. 139–150, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Urbanek, D. Cesselli, M. Rota et al., “Stem cell niches in the adult mouse heart,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 24, pp. 9226–9231, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. A. A. Matar and J. J. Chong, “Stem cell therapy for cardiac dysfunction,” SpringerPlus, vol. 3, article 440, 2014. View at Publisher · View at Google Scholar
  17. E. Messina, L. de Angelis, G. Frati et al., “Isolation and expansion of adult cardiac stem cells from human and murine heart,” Circulation Research, vol. 95, no. 9, pp. 911–921, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. K. U. Hong and R. Bolli, “Cardiac stem cell therapy for cardiac repair,” Current Treatment Options in Cardiovascular Medicine, vol. 16, no. 7, article 324, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Hu, G. Yan, W. He, Z. Liu, H. Xu, and G. Ma, “The influence of disease and age on human cardiac stem cells,” Annals of Clinical Biochemistry, vol. 51, part 5, pp. 582–590, 2014. View at Google Scholar
  20. M. C. Capogrossi, “Cardiac stem cells fail with aging: a new mechanism for the age-dependent decline in cardiac function,” Circulation Research, vol. 94, no. 4, pp. 411–413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. D. H. J. Thijssen, D. Torella, M. T. E. Hopman, and G. M. Ellison, “The role of endothelial progenitor and cardiac stem cells in the cardiovascular adaptations to age and exercise,” Frontiers in Bioscience, vol. 14, no. 12, pp. 4685–4702, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Anversa, M. Rota, K. Urbanek et al., “Myocardial aging: a stem cell problem,” Basic Research in Cardiology, vol. 100, no. 6, pp. 482–493, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Saravanakumar and H. Devaraj, “Distribution and homing pattern of c-kit+ Sca-1+ CXCR4+ resident cardiac stem cells in neonatal, postnatal, and adult mouse heart,” Cardiovascular Pathology, vol. 22, no. 4, pp. 257–263, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. R. R. Smith, L. Barile, H. C. Cho et al., “Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens,” Circulation, vol. 115, no. 7, pp. 896–908, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Bolli, A. R. Chugh, D. D'Amario et al., “Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial,” The Lancet, vol. 378, no. 9806, pp. 1847–1857, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. R. R. Makkar, R. R. Smith, K. Cheng et al., “Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial,” The Lancet, vol. 379, no. 9819, pp. 895–904, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Malliaras, R. R. Makkar, R. R. Smith et al., “Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-derived aUtologous stem CElls to reverse ventricular dysfunction),” Journal of the American College of Cardiology, vol. 63, no. 2, pp. 110–122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. A. R. Chugh, G. M. Beache, J. H. Loughran et al., “Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance,” Circulation, vol. 126, no. 11, supplement 1, pp. S54–S64, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. M. Hare, J. E. Fishman, G. Gerstenblith et al., “Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial,” The Journal of the American Medical Association, vol. 308, no. 22, pp. 2369–2379, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. A. W. Heldman, D. L. DiFede, J. E. Fishman et al., “Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial,” Journal of the American Medical Association, vol. 311, no. 1, pp. 62–73, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Hansen, S. Nyby, J. Eifer Møller et al., “Intracoronary injection of CD34+-cells in chronic ischemic heart failure: 7 years follow-up of the dancell study,” Cardiology, vol. 129, no. 2, pp. 69–74, 2014. View at Publisher · View at Google Scholar
  32. J. Lee, S. Lee, Y. Youn et al., “A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction,” Journal of Korean Medical Science, vol. 29, no. 1, pp. 23–31, 2014. View at Publisher · View at Google Scholar
  33. V. Y. Suncion, E. Ghersin, J. E. Fishman et al., “Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: an analysis from the percutaneous stem cell injection delivery effects on neomyogenesis (POSEIDON) randomized trial,” Circulation Research, vol. 114, no. 8, pp. 1292–1301, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. B.-E. Strauer, M. Yousef, and C. M. Schannwell, “The acute and long-term effects of intracoronary stem cell transplantation in 191 patients with chronic heARt failure: the STAR-heart study,” European Journal of Heart Failure, vol. 12, no. 7, pp. 721–729, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Hu, S. Liu, Z. Zheng et al., “Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure: a single-center, randomized, double-blind, placebo-controlled clinical trial,” Journal of the American College of Cardiology, vol. 57, no. 24, pp. 2409–2415, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. F. Rodrigo, J. van Ramshorst, S. L. Beeres et al., “Intramyocardial injection of bone marrow mononuclear cells in chronic myocardial ischemia patients after previous placebo injection improves myocardial perfusion and anginal symptoms: an intra-patient comparison,” American Heart Journal, vol. 164, no. 5, pp. 771–778, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Antonitsis, K. Anastasiadis, G. Koliakos et al., “Intramyocardial implantation of autologous bone marrow-derived stem cells combined with coronary artery bypass grafting in patients with ischemic cardiomyopathy: a pilot study,” Hippokratia, vol. 16, no. 4, pp. 366–370, 2012. View at Google Scholar · View at Scopus
  38. E. C. Perin, J. T. Willerson, C. J. Pepine et al., “Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial,” Journal of the American Medical Association, vol. 307, no. 16, pp. 1717–1726, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Sürder, R. Manka, V. Lo Cicero et al., “Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: Effects on global left ventricular function,” Circulation, vol. 127, no. 19, pp. 1968–1979, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Santoso, C. W. Siu, C. Irawan et al., “Endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic heart failure: a randomized placebo-controlled trial (END-HF),” Journal of Cardiovascular Translational Research, vol. 7, no. 6, pp. 545–552, 2014. View at Publisher · View at Google Scholar
  41. B. Assmus, A. Rolf, S. Erbs et al., “Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction,” Circulation: Heart Failure, vol. 3, no. 1, pp. 89–96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. D. M. Leistner, U. Fischer-Rasokat, J. Honold et al., “Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy,” Clinical Research in Cardiology, vol. 100, no. 10, pp. 925–934, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. A. R. Williams, B. Trachtenberg, D. L. Velazquez et al., “Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling,” Circulation Research, vol. 108, no. 7, pp. 792–796, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Wang, J. Cui, W. Peng, and M. Lu, “Intracoronary autologous CD34+ stem cell therapy for intractable angina,” Cardiology, vol. 117, no. 2, pp. 140–147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. D. W. Losordo, T. D. Henry, C. Davidson et al., “Intramyocardial, autologous CD34+ cell therapy for refractory angina,” Circulation Research, vol. 109, no. 4, pp. 428–436, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Poglajen, M. Sever, M. Cukjati et al., “Effects of transendocardial CD34+ Cell transplantation in patients with ischemic cardiomyopathy,” Circulation: Cardiovascular Interventions, vol. 7, no. 4, pp. 552–559, 2014. View at Publisher · View at Google Scholar
  47. S. Mansour, D.-C. Roy, V. Bouchard et al., “COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: Study rationale and design,” Journal of Cardiovascular Translational Research, vol. 3, no. 2, pp. 153–159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Mansour, D.-C. Roy, V. Bouchard et al., “COMPARE-AMI trial: Comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: study rationale and design,” Journal of Cardiovascular Translational Research, vol. 3, no. 2, pp. 153–159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. U. Kurbonov, A. Dustov, A. Barotov et al., “Intracoronary infusion of autologous CD133+ cells in myocardial infarction and tracing by Tc99m MIBI scintigraphy of the heart areas involved in cell homing,” Stem Cells International, vol. 2013, Article ID 582527, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Forcillo, L.-M. Stevens, S. Mansour et al., “Implantation of CD133+ stem cells in patients undergoing coronary bypass surgery: IMPACT-CABG pilot trial,” Canadian Journal of Cardiology, vol. 29, no. 4, pp. 441–447, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Assmann, M. Heke, P. Kröpil et al., “Laser-supported CD133+ cell therapy in patients with ischemic cardiomyopathy: initial results from a prospective phase I multicenter trial,” PLoS ONE, vol. 9, no. 7, Article ID e101449, 2014. View at Publisher · View at Google Scholar
  52. B. A. Nasseri, W. Ebell, M. Dandel et al., “Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial,” European Heart Journal, vol. 35, no. 19, pp. 1263–1274, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Fujita, T. Sakaguchi, S. Miyagawa et al., “Clinical impact of combined transplantation of autologous skeletal myoblasts and bone marrow mononuclear cells in patients with severely deteriorated ischemic cardiomyopathy,” Surgery Today, vol. 41, no. 8, pp. 1029–1036, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Brickwedel, H. Gulbins, and H. Reichenspurner, “Long-term follow-up after autologous skeletal myoblast transplantation in ischaemic heart disease,” Interactive Cardiovascular and Thoracic Surgery, vol. 18, no. 1, pp. 61–66, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Dimmeler and A. M. Zeiher, “Cell therapy of acute myocardial infarction: open questions,” Cardiology, vol. 113, no. 3, pp. 155–160, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. L. B. Balsam, A. J. Wagers, J. L. Christensen, T. Kofidis, I. L. Weissmann, and R. C. Robbins, “Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium,” Nature, vol. 428, no. 6983, pp. 668–673, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Zhang, P. Zhang, J. Guo et al., “Enhanced cytoprotection and angiogenesis by bone marrow cell transplantation may contribute to improved ischemic myocardial function,” European Journal of Cardio-Thoracic Surgery, vol. 25, no. 2, pp. 188–195, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Y. Sheikh, S.-A. Lin, F. Cao et al., “Molecular imaging of bone marrow mononuclear cell homing and engraftment in ischemic myocardium,” Stem Cells, vol. 25, no. 10, pp. 2677–2684, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. B. E. Strauer, M. Brehm, T. Zeus et al., “Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction,” Deutsche Medizinische Wochenschrift, vol. 126, no. 34-35, pp. 932–938, 2001. View at Publisher · View at Google Scholar
  60. T. Dill, V. Schächinger, A. Rolf et al., “Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy,” American Heart Journal, vol. 157, no. 3, pp. 541–547, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. J. S. Mills and S. V. Rao, “REPAIR-AMI: stem cells for acute myocardial infarction,” Future Cardiology, vol. 3, no. 2, pp. 137–140, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. V. Schächinger, S. Erbs, A. Elsässer et al., “Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial,” European Heart Journal, vol. 27, no. 23, pp. 2775–2783, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. V. Jeevanantham, M. Butler, A. Saad, A. Abdel-Latif, E. K. Zuba-Surma, and B. Dawn, “Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis,” Circulation, vol. 126, no. 5, pp. 551–568, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. K. Sadat, S. Ather, W. Aljaroudi, J. Heo, A. E. Iskandrian, and F. G. Hage, “The effect of bone marrow mononuclear stem cell therapy on left ventricular function and myocardial perfusion,” Journal of Nuclear Cardiology, vol. 21, no. 2, pp. 351–367, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. R. de Jong, J. H. Houtgraaf, S. Samiei, E. Boersma, and H. J. Duckers, “Intracoronary stem cell infusion after acute myocardial infarction: a meta-analysis and update on clinical trials,” Circulation: Cardiovascular Interventions, vol. 7, no. 2, pp. 156–167, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Dominici, K. Le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999. View at Publisher · View at Google Scholar · View at Scopus
  68. X.-J. Wang and Q.-P. Li, “The roles of mesenchymal stem cells (MSCs) therapy in ischemic heart diseases,” Biochemical and Biophysical Research Communications, vol. 359, no. 2, pp. 189–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. J. M. Ryan, F. P. Barry, J. M. Murphy, and B. P. Mahon, “Mesenchymal stem cells avoid allogeneic rejection,” Journal of Inflammation, vol. 2, article 8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. Q. Yu, Q. Li, R. Na et al., “Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathy,” Molecular and Cellular Biochemistry, vol. 387, no. 1-2, pp. 279–285, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. S. L. Chen, W. W. Fang, J. Qian et al., “Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction,” Chinese Medical Journal, vol. 117, no. 10, pp. 1443–1448, 2004. View at Google Scholar
  72. J. M. Hare, J. H. Traverse, T. D. Henry et al., “A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction,” Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2277–2286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. X. Wang, W. C. Xi, and F. Wang, “The beneficial effects of intracoronary autologous bone marrow stem cell transfer as an adjunct to percutaneous coronary intervention in patients with acute myocardial infarction,” Biotechnology Letters, vol. 36, no. 11, pp. 2163–2168, 2014. View at Publisher · View at Google Scholar
  74. S. A. Fisher, C. Dorée, S. J. Brunskill, A. Mathur, and E. Martin-Rendon, “Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis,” PLoS ONE, vol. 8, no. 6, Article ID e64669, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. A. N. Nowbar, M. Mielewczik, M. Karavassilis et al., “Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis,” The British Medical Journal, vol. 348, Article ID g2688, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. S. A. Fisher, S. J. Brunskill, C. Doree, A. Mathur, D. P. Taggart, and E. Martin-Rendon, “Stem cell therapy for chronic ischaemic heart disease and congestive heart failure,” Cochrane Database of Systematic Reviews, vol. 4, Article ID CD007888, 2014. View at Publisher · View at Google Scholar
  77. J. J. Minguell and A. Erices, “Mesenchymal stem cells and the treatment of cardiac disease,” Experimental Biology and Medicine, vol. 231, no. 1, pp. 39–49, 2006. View at Google Scholar · View at Scopus
  78. J. D. Dowell, M. Rubart, K. B. S. Pasumarthi, M. H. Soonpaa, and L. J. Field, “Myocyte and myogenic stem cell transplantation in the heart,” Cardiovascular Research, vol. 58, no. 2, pp. 336–350, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Nomura, E. Ashihara, K. Tateishi et al., “Skeletal myosphere-derived progenitor cell transplantation promotes neovascularization in delta-sarcoglycan knockdown cardiomyopathy,” Biochemical and Biophysical Research Communications, vol. 352, no. 3, pp. 668–674, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. N. Dib, J. Dinsmore, Z. Lababidi et al., “One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study),” JACC: Cardiovascular Interventions, vol. 2, no. 1, pp. 9–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. N. Dib, P. McCarthy, A. Campbell et al., “Feasibility and safety of autologous myoblast transplantation in patients with ischemic cardiomyopathy,” Cell Transplantation, vol. 14, no. 1, pp. 11–19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. H. Ince, M. Petzsch, T. C. Rehders, S. Kische, T. Chatterjee, and C. A. Nienaber, “Percutaneous transplantation of autologous myoblasts in ischemic cardiomyopathy,” Herz, vol. 30, no. 3, pp. 223–231, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. P. Menasché, A. A. Hagège, J.-T. Vilquin et al., “Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction,” Journal of the American College of Cardiology, vol. 41, no. 7, pp. 1078–1083, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. C. E. Veltman, O. I. I. Soliman, M. L. Geleijnse et al., “Four-year follow-up of treatment with intramyocardial skeletal myoblasts injection in patients with ischaemic cardiomyopathy,” European Heart Journal, vol. 29, no. 11, pp. 1386–1396, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Wang, S. Zhang, B. Rabinovich et al., “Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action,” Circulation Research, vol. 106, no. 12, pp. 1904–1911, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. E. C. Perin and J. T. Willerson, “CD34+ autologous human stem cells in treating refractory angina,” Circulation Research, vol. 109, no. 4, pp. 351–352, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. T. J. Povsic, C. Junge, A. Nada et al., “A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the renew study,” American Heart Journal, vol. 165, no. 6, pp. 854.e2–861.e2, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Manginas, E. Goussetis, M. Koutelou et al., “Pilot study to evaluate the safety and feasibility of intracoronary CD133+ and CD133- CD34+ cell therapy in patients with nonviable anterior myocardial infarction,” Catheterization and Cardiovascular Interventions, vol. 69, no. 6, pp. 773–781, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. H. Ahmadi, H. Baharvand, S. K. Ashtiani et al., “Safety analysis and improved cardiac function following local autologous transplantation of CD133+ enriched bone marrow cells after myocardial infarction,” Current Neurovascular Research, vol. 4, no. 3, pp. 153–160, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Kurtz, “Mesenchymal stem cell delivery routes and fate,” International Journal of Stem Cells, vol. 1, no. 1, pp. 1–7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. A. W. Heldman and J. M. Hare, “Cell therapy for myocardial infarction: special delivery,” Journal of Molecular and Cellular Cardiology, vol. 44, no. 3, pp. 473–476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. J. H. Loughran, J. B. Elmore, M. Waqar, A. R. Chugh, and R. Bolli, “Cardiac stem cells in patients with ischemic cardiomyopathy: discovery, translation, and clinical investigation,” Current Atherosclerosis Reports, vol. 14, no. 5, pp. 491–503, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. T. I. G. van der Spoel, S. J. Jansen of Lorkeers, P. Agostoni et al., “Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease,” Cardiovascular Research, vol. 91, no. 4, pp. 649–658, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. R. T. van Beem, A. Hirsch, I. M. Lommerse et al., “Recovery and functional activity of mononuclear bone marrow and peripheral blood cells after different cell isolation protocols used in clinical trials for cell therapy after acute myocardial infarction,” EuroIntervention, vol. 4, no. 1, pp. 133–138, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. F. H. Seeger, T. Tonn, N. Krzossok, A. M. Zeiher, and S. Dimmeler, “Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction,” European Heart Journal, vol. 28, no. 6, pp. 766–772, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. B. Assmus, T. Tonn, F. H. Seeger et al., “Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy,” Journal of the American College of Cardiology, vol. 55, no. 13, pp. 1385–1394, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. P. J. Hanley, Z. Mei, A. G. Durett et al., “Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System,” Cytotherapy, vol. 16, no. 8, pp. 1048–1058, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. J. H. Traverse, T. D. Henry, C. J. Pepine et al., “Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial,” The Journal of the American Medical Association, vol. 308, no. 22, pp. 2380–2389, 2012. View at Publisher · View at Google Scholar
  99. S. Zhang, A. Sun, D. Xu et al., “Impact of timing on efficacy and safetyof intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: a pooled subgroup analysis of randomized controlled trials,” Clinical Cardiology, vol. 32, no. 8, pp. 458–466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Blatt, S. Minha, G. Moravsky, Z. Vered, and R. Krakover, “Intracoronary administration of autologous bone marrow mononuclear cells in patients with chronic ischemic symptomatic cardiomyopathy: 5 years follow-up,” Israel Medical Association Journal, vol. 12, no. 12, pp. 738–741, 2010. View at Google Scholar · View at Scopus
  101. K. Cheng, K. Malliaras, R. R. Smith et al., “Human cardiosphere-derived cells from advanced heart failure patients exhibit augmented functional potency in myocardial repair,” JACC: Heart Failure, vol. 2, no. 1, pp. 49–61, 2014. View at Publisher · View at Google Scholar · View at Scopus
  102. L. N. Maslov, Y. K. Podoksenov, A. G. Portnichenko, and A. V. Naumova, “Hypoxic preconditioning of stem cells as a new approach to increase the efficacy of cell therapy for myocardial infarction,” Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, no. 12, pp. 16–25, 2013. View at Google Scholar · View at Scopus
  103. H.-H. Lu, Y.-F. Li, Z.-Q. Sheng, and Y. Wang, “Preconditioning of stem cells for the treatment of myocardial infarction,” Chinese Medical Journal, vol. 125, no. 2, pp. 378–384, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. X. Hu, S. P. Yu, J. L. Fraser et al., “Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis,” Journal of Thoracic and Cardiovascular Surgery, vol. 135, no. 4, pp. 799–808, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. B. Assmus, D. H. Walter, F. H. Seeger et al., “Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial,” The Journal of the American Medical Association, vol. 309, no. 15, pp. 1622–1631, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. J. L. Herrmann, Y. Wang, A. M. Abarbanell, B. R. Weil, J. Tan, and D. R. Meldrum, “Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection,” Shock, vol. 33, no. 1, pp. 24–30, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. Y. Luo, Y. Wang, J. A. Poynter et al., “Pretreating mesenchymal stem cells with interleukin-1β and transforming growth factor-β synergistically increases vascular endothelial growth factor production and improves mesenchymal stem cell-mediated myocardial protection after acute ischemia,” Surgery, vol. 151, no. 3, pp. 353–363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. N. Takehara, Y. Tsutsumi, K. Tateishi et al., “Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction,” Journal of the American College of Cardiology, vol. 52, no. 23, pp. 1858–1865, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Chen, A. R. Baydoun, R. Xu et al., “Lysophosphatidic acid protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis,” Stem Cells, vol. 26, no. 1, pp. 135–145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. X. Liu, J. Hou, L. Shi et al., “Lysophosphatidic acid protects mesenchymal stem cells against ischemia-induced apoptosis in vivo,” Stem Cells and Development, vol. 18, no. 7, pp. 947–953, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. X. Y. Wang, X. S. Fan, L. Cai, S. Liu, X. F. Cong, and X. Chen, “Lysophosphatidic acid rescues bone mesenchymal stem cells from hydrogen peroxide-induced apoptosis,” Apoptosis, vol. 20, no. 3, pp. 273–284, 2015. View at Publisher · View at Google Scholar
  112. Q. Zhang, H. Wang, Y. J. Yang et al., “Atorvastatin treatment improves the effects of mesenchymal stem cell transplantation on acute myocardial infarction: the role of the RhoA/ROCK/ERK pathway,” International Journal of Cardiology, vol. 176, no. 3, pp. 670–679, 2014. View at Publisher · View at Google Scholar
  113. J. S. Park, S. Suryaprakash, Y. H. Lao, and K. W. Leong, “Engineering mesenchymal stem cells for regenerative medicine and drug delivery,” Methods, 2015. View at Publisher · View at Google Scholar
  114. P. T. Yin, E. Han, and K. B. Lee, “Engineering stem cells for biomedical applications,” Advanced Healthcare Materials, 2015. View at Publisher · View at Google Scholar
  115. A. E. Mayfield, E. L. Tilokee, N. Latham et al., “The effect of encapsulation of cardiac stem cells within matrix-enriched hydrogel capsules on cell survival, post-ischemic cell retention and cardiac function,” Biomaterials, vol. 35, no. 1, pp. 133–142, 2014. View at Publisher · View at Google Scholar · View at Scopus
  116. E. G. Schmuck, J. D. Mulligan, R. L. Ertel et al., “Cardiac fibroblast-derived 3D extracellular matrix seeded with mesenchymal stem cells as a novel device to transfer cells to the ischemic myocardium,” Cardiovascular Engineering and Technology, vol. 5, no. 1, pp. 119–131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. R. Santhakumar, P. Vidyasekar, and R. S. Verma, “Cardiogel: a nano-matrix scaffold with potential application in cardiac regeneration using mesenchymal stem cells,” PLoS ONE, vol. 9, no. 12, Article ID e114697, 2014. View at Publisher · View at Google Scholar
  118. Y. Miyahara, N. Nagaya, M. Kataoka et al., “Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction,” Nature Medicine, vol. 12, no. 4, pp. 459–465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. S. Miyagawa, G. Matsumiya, T. Funatsu et al., “Combined autologous cellular cardiomyoplasty using skeletal myoblasts and bone marrow cells for human ischemic cardiomyopathy with left ventricular assist system implantation: report of a case,” Surgery Today, vol. 39, no. 2, pp. 133–136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. A. R. Williams, K. E. Hatzistergos, B. Addicott et al., “Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction,” Circulation, vol. 127, no. 2, pp. 213–223, 2013. View at Publisher · View at Google Scholar · View at Scopus